CD80 and hematopoietic and lymphoid cell neoplasm: Whereas RAJI-CD80/CD86-negative and NCI-H929 cells were utilized with bsAbs targeting hematologic cancers, such as CD20xCD3 and BCMAxCD3, respectively.